{
  "trial_id": "NCT00481832",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age",
      "label": "met",
      "evidence": "64yo woman"
    },
    {
      "criterion": "Histologically proven non-Hodgkin's lymphoma",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Relapse after achieving initial remission or failure to achieve initial remission",
      "label": "met",
      "evidence": "relapse of her myeloma"
    },
    {
      "criterion": "KPS > 70%",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Matched related or unrelated donor identified and available",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Recent Bone marrow biopsy and cytogenetic analysis",
      "label": "met",
      "evidence": "Bone marrow biopsy"
    },
    {
      "criterion": "Patients must have a pretreatment serum bilirubin < 2 x the institutional ULN",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Patients must have an EKG within 42 days prior to registration that shows no significant abnormalities",
      "label": "met",
      "evidence": "EKG"
    },
    {
      "criterion": "Patients must have a corrected diffusion capacity > 50% prior to the autologous transplant and > 40% prior to the allogeneic transplant",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Patients with known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible",
      "label": "not_met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or breast-feeding women are ineligible due to the known birth defects association with the treatments used in this study",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Patients known to be human immunodeficiency virus (HIV)-positive are ineligible because the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "No prior autologous or allogeneic hematopoietic cell transplantation",
      "label": "met",
      "evidence": "no prior autologous or allogeneic hematopoietic cell transplantation"
    },
    {
      "criterion": "Donor Selection/Evaluation: Related or unrelated HLA identical donors who are in good health and have no contra-indication to donation",
      "label": "not_met",
      "evidence": ""
    }
  ],
  "notes": "Patient has multiple myeloma with recurrent disease, systemic amyloidosis, and ESRD. She was treated with various regimens including melphalan, prednisone, VAD, thalidomide, and velcade.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT00481832",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}